Antibody Cocktail COVID-19 Treatment Trials Begin in Oxnard
Two Studies, One Location
Nicholas Focil, CEO of FOMAT, announced the launch of two separate clinical trials involving an antibody cocktail COVID-19 treatment. The trials are being conducted at a site located across from the Oxnard Library, where members of the public can access free COVID-19 testing beginning on a Thursday enrollment window.
The process is straightforward. Participants arrive for a free test and receive their results within an hour. Those who test positive may qualify to enroll in the treatment study, which involves the antibody cocktail COVID-19 therapy. Those who test negative may be eligible for the second study, which is designed for healthy individuals at high risk of exposure.
“This medication is a one-treatment day — you get treated the same day, and for the next 45 days you will follow up with 15 visits,” Focil explained. For participants in the prevention arm of the trial, the protocol extends further: qualifying individuals receive the investigational medication and are monitored for a period of seven months.
Why This Antibody Cocktail Matters
Antibody cocktails — also called monoclonal antibody therapies — work by introducing laboratory-engineered proteins that mimic the immune system’s ability to fight off a specific pathogen. Unlike vaccines, which train the immune system over time, monoclonal antibody treatments are designed to provide immediate protection or therapeutic benefit upon administration. This makes them especially valuable for individuals who have already been exposed or who are at elevated risk due to age, underlying health conditions, or frequent contact with infected individuals.
The antibody cocktail COVID-19 treatment being studied at the FOMAT site in Oxnard attracted national attention because of its potential to address two critical gaps: early treatment for those who test positive before symptoms become severe, and preventive protection for high risk individuals who have not yet been exposed.
Community Access and Minority Inclusion
One of the defining features of FOMAT’s approach to clinical research is its commitment to reaching underrepresented communities. Oxnard has a large Latino population, a demographic that was disproportionately affected by COVID-19 due to higher rates of essential worker exposure, multigenerational households, and limited access to early healthcare. By situating the trial site in a central, accessible location and offering free testing, FOMAT worked to remove the barriers that have historically kept minority populations out of clinical research.
Focil has consistently emphasized that diverse trial enrollment is not just an ethical priority — it is a scientific one. Treatment data drawn from homogeneous populations produces outcomes that may not generalize across all patient groups. Building diversity into the trial from the start leads to more robust, widely applicable results.
About FOMAT’s Clinical Research Network
FOMAT has over a decade of experience conducting Phase I through Phase IV clinical trials across a broad range of therapeutic areas, including infectious disease, oncology, ophthalmology, and metabolic conditions. Its investigator network spans sites across the United States, giving sponsors and CROs access to experienced teams and diverse patient populations capable of meeting the demands of complex multi site studies.
To learn more about active studies currently enrolling, or to explore FOMAT’s clinical trial capabilities, visit fomatmedical.com.
For More Information
- To read the original CBS Los Angeles report, click here
- To contact FOMAT about study participation: (805) 483-1184 or [email protected]